DESTINY-Breast02
07 Dec 2020
Daiichi
NCT03523585
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study of Trastuzumab Deruxtecan (DS-8201a), an Anti-HER2-antibody Drug Conjugate, Versus Treatment of Investigator’s Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Subjects Pretreated With Prior Standard of Care HER2 Therapies, Including T-DM1
Daiichi Sankyo, Inc.
Cancer Type | Breast |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 18 years and older |
Sex | Both |
Tumour Stream | - |
Cancer Stage | Locally Recurrent or Locally Advanced, Metastatic or Widespread |
Anticipated Start Date | 2018-08-01 |
Anticipated End Date | 2022-02-01 |
Hospital | Ashford Cancer Centre Research |
---|---|
Clinical Trial Coordinator | Sue Yeend |
syeend@adelaidecancercentre.com.au | |
Phone | 08 8292 2240 |
Principal Investigator | Dr Meena Okera |
Recruitment Status | Recruiting |
Hospital | Calvary North Adelaide Hospital |
---|---|
Clinical Trial Coordinator | Julie Rowe |
julie.rowe@calvarycare.org.au | |
Phone | 08 8239 9536 |
Principal Investigator | Dr Sid Selva |
Recruitment Status | Recruiting |